HealthCor Management L.P. increased its position in shares of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) by 8.6% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 2,800,000 shares of the company’s stock after buying an additional 221,960 shares during the quarter. Pacira Pharmaceuticals comprises 4.2% of HealthCor Management L.P.’s investment portfolio, making the stock its 9th biggest holding. HealthCor Management L.P. owned about 6.90% of Pacira Pharmaceuticals worth $127,820,000 at the end of the most recent quarter.
Other large investors have also recently added to or reduced their stakes in the company. Nationwide Fund Advisors lifted its position in Pacira Pharmaceuticals by 50.5% during the 3rd quarter. Nationwide Fund Advisors now owns 100,534 shares of the company’s stock worth $3,775,000 after acquiring an additional 33,734 shares during the period. Pictet Asset Management Ltd. acquired a new stake in Pacira Pharmaceuticals during the 3rd quarter worth approximately $1,929,000. Dupont Capital Management Corp lifted its position in Pacira Pharmaceuticals by 13.7% during the 3rd quarter. Dupont Capital Management Corp now owns 15,090 shares of the company’s stock worth $567,000 after acquiring an additional 1,821 shares during the period. Swiss National Bank lifted its position in Pacira Pharmaceuticals by 6.3% during the 3rd quarter. Swiss National Bank now owns 67,100 shares of the company’s stock worth $2,520,000 after acquiring an additional 4,000 shares during the period. Finally, Alps Advisors Inc. lifted its position in Pacira Pharmaceuticals by 9.8% during the 3rd quarter. Alps Advisors Inc. now owns 39,731 shares of the company’s stock worth $1,492,000 after acquiring an additional 3,546 shares during the period.
A number of research firms have weighed in on PCRX. Zacks Investment Research raised Pacira Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, March 6th. BMO Capital Markets decreased their price objective on Pacira Pharmaceuticals from $32.00 to $31.00 and set a “market perform” rating for the company in a research report on Thursday, March 1st. Royal Bank of Canada set a $44.00 price objective on Pacira Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, March 1st. HC Wainwright set a $45.00 price objective on Pacira Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, March 1st. Finally, Oppenheimer reaffirmed a “hold” rating on shares of Pacira Pharmaceuticals in a research report on Thursday, March 1st. Three analysts have rated the stock with a sell rating, twelve have given a hold rating and eight have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $45.29.
Pacira Pharmaceuticals Inc (NASDAQ:PCRX) opened at $31.90 on Monday. Pacira Pharmaceuticals Inc has a 1-year low of $29.35 and a 1-year high of $52.47. The company has a quick ratio of 6.22, a current ratio of 6.96 and a debt-to-equity ratio of 0.99.
Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its quarterly earnings data on Wednesday, February 28th. The company reported $0.38 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.46. The firm had revenue of $79.08 million during the quarter, compared to analysts’ expectations of $79.06 million. Pacira Pharmaceuticals had a negative return on equity of 8.55% and a negative net margin of 14.87%. Pacira Pharmaceuticals’s revenue was up 8.5% on a year-over-year basis. During the same period in the previous year, the firm posted $0.09 earnings per share. research analysts predict that Pacira Pharmaceuticals Inc will post -0.24 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This story was first posted by American Banking News and is the property of of American Banking News. If you are accessing this story on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.americanbankingnews.com/2018/03/12/pacira-pharmaceuticals-inc-pcrx-position-lifted-by-healthcor-management-l-p.html.
About Pacira Pharmaceuticals
Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.
Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.